Please join us as we speak to Dr. Matthew Davids of Dana-Farber Cancer Institute. In this episode, Dr. Davids discusses current treatments for chronic lymphocytic leukemia (CLL) and the exciting possibilities for the future using immunotherapies.

Dr. Davids shares how the goal of treatment is long term remission and quality of life. Since 2010, BTK Inhibitors, CAR T-cell therapy and other treatments have come on the market and have increased the possibilities for patients to live a long life with CLL.

Mentioned on this episode: 

• Chronic Lymphocyctic Leukemia (CLL)
• How CAR T Cell Therapy Gives Hope to Cancer Patients Podcast Episode
• CURE Magazine Article on CAR T and Young CLL Patients
• American Journal of Managed Care – CAR T cells persist
• Minimal/Measurable Residual Disease (MRD) Fact Sheet
• CAR T-cell Therapy
• CAR T-Cell Therapy Webinar
• How CAR T-Cell Therapy Works In Augmented Reality
• Stem Cell Transplant
• Allogeneic Stem Cell Transplant
• Autologous Stem Cell Transplant
• LLS COVID-19 Resources
• Clinical Trial Support Center
• The Bloodline Subscriber Lounge

Additional LLS Support Resources: 

• Information Specialists
• Financial support
• Free telephone/web patient programs 
• Patti Robinson Kaufmann First Connection Program
• Free booklets 
• Online chats 
• Caregiver support 
• Support groups 
• Free Nutrition Consultations 
• LLS Advocacy
• Survivorship Workbook

Support for this episode provided by BeiGene USA, Inc.; Bristol Myers Squibb; Genentech, Inc. & Biogen; Loxo Oncology at Lilly and Pharmacyclics, An AbbVie Company & Janssen Biotech, and Thomas D. Oxley Fund for CLL Patient Education and Support.

The post Achieving Long-term Remission with Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with Blood Cancer United Podcast.

Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.

Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Bristol Myers Squibb; CRISPR Therapeutics; Janssen Oncology & Legend Biotech; KITE, a Gilead Company and Novartis Pharmaceuticals Corporation.

The post Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy first appeared on The Bloodline with Blood Cancer United Podcast.

Join us as we speak with Charles Huang and Dr. Gabriel Mannis in honor of AML Awareness Day (April 21st). In this episode, Charles tells us about his treatment for AML, participation in clinical trials, and shares about his struggle to find a bone marrow donor as an Asian Pacific Islander. Charles then turned his struggle into legislation to make it easier to join a bone marrow donor registry to save lives. Dr. Mannis, of Stanford Medicine, shares about the latest advances in AML research, from clinical trials in Chimeric Antigen Receptor (CAR) therapy to medications that reduce graft-vs-host disease (GVHD). With research advancing quickly in the field of AML treatment, patients and caregivers are given reasons to have hope after the uncertainty of a diagnosis.

Mentioned on this episode: 

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes (MDS)
• Minimal/Measurable Residual Disease
• CAR T-cell Therapy
• Stem Cell Transplant
• Graft-Vs-Host-Disease (GVHD)
• Charlie’s Law
• Be The Match – Bone Marrow Donor Registry
• LLS Advocacy & Public Policy
• Innovative Therapies in Acute Leukemias podcast episode

Additional LLS Support Resources: 

• Information Specialists
• Free telephone/web patient programs 
• Clinical Trial Support Center
• Free booklets 
• Financial support
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Free Nutrition Consultations 
• LLS Myeloma Link
• Patti Robinson Kaufmann First Connection Program 
• Young Adult Resources
• Survivorship Workbook

Support for this episode provided by Astellas and Genentech, Inc & Biogen.

The post Patient-Doctor Perspectives: Hope in the Uncertainty of AML first appeared on The Bloodline with Blood Cancer United Podcast.

Join us as we speak to Dr. Eunice Wang, the Chief of Leukemia Service and Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. In this episode, Dr. Wang delves into the rare blood cancer, blastic plasmacytoid dendritic cell neoplasm (BPDCN). Usually identified by characteristic deep purple lesions, oncologists continue to raise awareness of this rare diagnosis, as swift referral and treatment usually leads to better outcomes. After being universally identified as BPDCN by World Health Organization (WHO) in 2018, clinical trials and CAR T-cell therapies have brought new hope to BPDCN patients.

Mentioned on this episode: 

• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
• Why Roswell Park for Leukemia & Blood Cancers 
• Stem Cell Transplantation
• CAR T-cell Therapy
• Clinical Trial Support Center

Additional LLS Support Resources: 

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program 
• Free Nutrition Consultations 
• LLS Advocacy
• LLS Myeloma Link

Support for this episode provided by ImmunoGen.

The post Hope for Rare Cancers: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) first appeared on The Bloodline with Blood Cancer United Podcast.

Join us in this next installment of our series, Patient-Doctor Perspectives, where we explore a diagnosis from the view of a patient and doctor. In this episode, we speak to Dr. Larry Saltzman, a Chronic Lymphocytic Leukemia (CLL) survivor and physician researcher and Dr. Steven Coutre from Stanford Medicine. Dr. Larry shares his experience living with CLL, participating in LLS Team In Training events, and his current work with LLS studying patient outcomes and COVID-19 vaccine antibody response. Dr. Coutre then delves deeper into CLL treatments, responses to vaccines and what is on the horizon for new treatments and clinical trials. 

*Please note that this episode was recorded prior to the rise of the COVID Delta variant and release of booster shots. We encourage patients to consult with your physician regarding COVID-19 safety and vaccines. Preliminary results have also been released for the antibody study and can be found in the show notes below.

Mentioned on this episode:

• Chronic Lymphocytic Leukemia (CLL)
• Small Cell Lymphocytic Lymphoma (SLL)
• CAR T-cell Therapy
• Minimal Residual Disease
• Team In Training
• Financial support
• Clinical Trial Support Center
• LLS Patient Registry
• Vaccines for Blood Cancer Patients
• LLS COVID-19 Antibody Research Study: Your Questions Answered

Additional LLS Support Resources:

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program 
• Free Nutrition Consultations 

Support for this episode provided by Genentech, Inc. & Biogen and Pharmacyclics, An AbbVie Company & Janssen Biotech.

The post Patient-Doctor Perspectives: CLL and a Decade of Transformation first appeared on The Bloodline with Blood Cancer United Podcast.

Join us as we speak to Dr. Caron Jacobson, an Assistant Professor of Medicine at Harvard Medical School and a lymphoma physician and researcher at the Dana-Farber Cancer Institute. In this episode, Dr. Jacobson shares about the use and benefits of CAR T-cell therapy in B-cell cancers, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). You will hear about how CAR T-cell therapy works, why it is used for B-cell cancers and the benefits of joining a clinical trial for this type of treatment.

Mentioned on this episode:

• CAR T-cell Therapy
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Chronic Lymphocytic Leukemia
• Immune Effector Cell Therapy Program – Dana-Farber Cancer Institute
• Clinical Trial Support Center

Additional LLS Support Resources:

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support – **Mantle Cell Lymphoma funding is OPEN** 
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program 
• Free Nutrition Consultations 

Support for this episode provided by Allogene; Bristol Myers Squibb; CRISPR Therapeutics; Kite, a Gilead Company; Janssen Oncology & Legend Biotech; and Novartis Pharmaceuticals.

The post How CAR T-cell Therapy Gives Hope to Cancer Patients first appeared on The Bloodline with Blood Cancer United Podcast.

Join us as we report on the latest developments in immunotherapy from the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition that was hosted virtually December 5-8, 2020. In this episode, we will be speaking to Dr. Laurie Sehn, a Clinical Professor and Researcher with the British Columbia Cancer Centre for Lymphoid Cancer and The University of British Columbia. Immunotherapy was a primary topic at this year’s ASH meeting. Dr. Sehn shares exciting news about the advancements in immunotherapy for Non-Hodgkin Lymphoma. Hear why lymphoma is a great candidate for immunotherapy, how it works, and how a collaboration of researchers from around the world is accelerating the number of new and effective treatments available for lymphoma patients.

This podcast episode is NOT an official program of the ASH annual meeting.

Support for this episode provided by Genentech and Pharmacyclics.

Mentioned

• The American Society of Hematology (ASH)
• BC Cancer Agency
• Chimeric Antigen Receptor T-Cell Therapy
• Immunotherapy
• Lymphoma

Additional

• Information Specialists
• Free telephone/web patient programs
• Free booklets
• Financial support
• Online chats
• Caregiver support
• LLS Community
• Support groups
• Patti Robinson Kaufmann First Connection Program
• Free Nutrition Consultations

The post Tackling Lymphoma: Recent Advances in Immunotherapy first appeared on The Bloodline with Blood Cancer United Podcast.

They say hindsight is always 20/20. Looking back, Tim Card remembers how his body may have been sending signals that something was wrong, but how he often attributed them to his active and busy lifestyle. Tim received his shocking lymphoma diagnosis after logging onto his medical portal, while awaiting test results. Tim is Penn State Cancer Institute’s first chimeric antigen receptor (CAR) t-cell therapy recipient, diffuse large B-cell lymphoma survivor and a father of 7. On this episode, Tim describes how he was diagnosed, when CAR T-cell therapy was introduced as a treatment option, side effects he experienced after CAR T-cell therapy, the importance of caregivers, and how humor helped him during the most challenging time of his life.

Please leave comment letting us know how you like the episode. Be sure to check out our other episodes about CAR T-cell therapy.

Mentioned on this episode:

• Chimeric Antigen Receptor (CAR) T-Cell Therapy
• Tim and Oya’s podcast

Additional LLS Support Resources:

• Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts
• CAR T-Cell Therapy Process
• Videos about CAR T-cell therapy
• Information Specialists
• Free telephone/web patient programs
• Free booklets
• Financial support
• Online chats
• Caregiver support
• LLS Community
• Support groups

Support for this episode provided by Allogene Therapeutics: Bristol Myers Squibb; CRISPR Therapeutics; Kite, A Gilead Company, and Novartis.

The post “The Only Way Through It, Is Through It”: Tim Card’s Story first appeared on The Bloodline with Blood Cancer United Podcast.

On this episode, Alicia and Lizette speak with Chuck Colletti, a two-time survivor of Stage 4 follicular lymphoma. Chuck was diagnosed in early 2016 when he underwent 7 months of chemotherapy which put his cancer into temporary remission. Unfortunately, 7 months later, it returned in a more aggressive form. With options dwindling, he was accepted into a CAR T-cell therapy clinical trial. Listen in as he describes how this therapy impacted his life both emotionally and physically, the side effects he experienced and the hope he has in this therapy’s ability to save many more lives.

DOWNLOAD TRANSCRIPT

Mentioned on this episode:

• Chimeric Antigen Receptor (CAR) T-Cell Therapy
• www.collettisurvivorsquad.org
• www.healthcentral.com

Additional LLS Support Resources:

• Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts
• CAR T-Cell Therapy Process
  
• Videos about CAR T-cell therapy
• Information Specialists
• Free telephone/web patient programs
• Free booklets
• Financial support
• Online chats
• Caregiver support
• LLS Community
• Support groups

Support for this episode provided by Celgene; Kite, A Gilead Company; and Novartis Oncology.

The post How CAR T-cell Therapy Saved My Life: Chuck’s Story first appeared on The Bloodline with Blood Cancer United Podcast.

On this episode, Alicia and Lizette speak with Dr. Rayne H. Rouce. Dr. Rouce is a pediatric hematologist and oncologist at Texas Children’s Cancer Center where she is a member of the Leukemia and Bone Marrow Transplant programs. She works as part of The Center for Cell and Gene Therapy at Baylor College of Medicine, focused on translating targeted T-cell therapies, and has been involved in every aspect of CAR T-cell development for clinical use.  On this episode, Dr. Rouce explains what types of cancers chimeric antigen receptor T-cell therapy, known as CAR T-cell therapy, currently treats, when it may be considered for treatment and why the recovery process may be different for each person. She addresses quality-of-life issues and recommends great questions about CAR T-cell therapy that a patient or caregiver should consider asking their healthcare team. Dr. Rouce shares her excitement for how she sees this therapy improving in the future and continues to work towards discovering how it can be a hopeful option for more and more patients.

DOWNLOAD TRANSCRIPT

Mentioned on this episode:

• CAR (chimeric antigen receptor) T-cell immunotherapy
• Clinical Trials
• Possible Side Effects of CAR T-Cell Therapy
• Clinical Trials
• Communicating with Your Specialist

Additional LLS Support Resources:

• CAR T-Cell Therapy Process
• Chimeric Antigen Receptor (CAR) T-Cell Therapy Facts
• Information Specialists
• Free telephone/web patient programs
• Free booklets
• Financial support
• Caregiver support
• Support groups

Support for this episode provided by Celgene; Kite, A Gilead Company; and Novartis.

The post CAR T-cell Explained: Recovering from CAR T-cell Therapy first appeared on The Bloodline with Blood Cancer United Podcast.